Upsher-Smith Laboratories
11
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
9.1%
1 terminated/withdrawn out of 11 trials
90.0%
+3.5% vs industry average
73%
8 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Role: lead
Vogelxo(R) ABPM Study in Hypogandal Men
Role: lead
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
Role: collaborator
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
Role: collaborator
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
Role: lead
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
Role: lead
Pharmacodynamics of Nasal and Buccal Midazolam Using EEG
Role: collaborator
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Role: lead
Assessment of Suicidality in Epilepsy - Rating Tools
Role: collaborator
Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms
Role: lead
SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
Role: collaborator
All 11 trials loaded